Cognitive dysfunction in the patient with antiphospholipid antibodies: considerations for cause and treatment.
The evidence supporting a causal relationship between antiphospholipid (aPL) antibodies and cognitive dysfunction is very limited despite a general impression that one exists. Patients with aPL antibodies may complain of cognitive difficulties in their everyday lives, forcing the clinician to examine this issue. As with other non-thrombotic antiphospholipid syndrome (APS) manifestations, cognitive dysfunction in this population should be approached as a diagnosis of exclusion. The complexity in diagnosing and treating various manifestations of rheumatic disease holds true for identifying and addressing cognitive decline in these patients.
Harrison
Melanie J
MJ
Hospital for Special Surgery, Weill Medical College of Cornell University, Department of Medicine, New York, NY 10021, USA. harrisonM@HSS.edu
Ravdin
Lisa D
LD
D017152:Antibodies, Antiphospholipid / Q000276:immunology*; D003072:Cognition Disorders / Q000276:immunology* / Q000628:therapy; D015928:Cognitive Behavioral Therapy / Q000379:methods*; D006801:Humans; D016896:Treatment Outcome
D017152:Antibodies, Antiphospholipid